A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

Summary

This clinical trial studies whether a web-based program, Kindred, works to improve the understanding of genetic cancer risk and cancer genetic testing in African American families. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or a family history of cancer means individuals are more likely to have a genetic change. If a genetic change is identified in a family, other relatives can choose to undergo hereditary cancer genetic testing to better understand their cancer risk. In families where a genetic change is not identified, or results are uncertain, relatives may also benefit from discussing their cancer risk with providers and, in some cases, getting hereditary cancer genetic testing themselves. Research has shown that African Americans are less likely than other racial groups to engage in cancer genetic testing. Kindred is an online tool that provides information so individuals can learn about their cancer genetic test results, how cancer genetic testing can help individuals and families understand their overall cancer risk (and strategies for reducing risk), and ways to talk with each other about cancer risk and health. This may be an effective way to improve the understanding of genetic cancer risk and cancer genetic testing in African American families.

Conditions

• BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome
• BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome
• Hereditary Neoplastic Syndrome
• Lynch Syndrome

Interventions

OTHER

Discussion

Ancillary studies

OTHER

Internet-Based Intervention

Receive access to the Kindred web-based portal

OTHER

Internet-Based Intervention

Share information and invite relatives

OTHER

Survey Administration

Ancillary studies

BEHAVIORAL

Telephone-Based Intervention

Receive check-in calls

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Michigan Rogel Cancer Center

  lead OTHER

Principal Investigators

• Katrina Ellis, MD · University of Michigan Rogel Cancer Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-06-15

Primary Completion

2028-06-30

Completion

2028-06-30

Countries

• United States

Study Locations